Literature DB >> 8934060

Ultrasonographic and endocrine evaluation of ovarian function among Norplant implants users with regular menses.

F Alvarez1, V Brache, A Faundes, A S Tejada, F Thevenin.   

Abstract

With the objective of evaluating the ovulatory function among long-term Norplant implants users with regular menstrual cycles, we undertook this prospective study including 11 Norplant implants users and 11 control women who were not using hormonal methods of fertility control. Exposed and unexposed women had had at least three regular menstrual cycles preceding enrollment. All women were followed during one menstrual cycle by serial vaginal ultrasound and estradiol (E2), progesterone (P), LH, and FSH measurements. Three Norplant implants users ovulated, three had luteinization of an unruptured follicle (LUF), three had persistent follicle growth up to a mean of 33 mm without rupture, and two had no follicular development beyond 16 mm. Ten of the controls had normal ovulation and one had LUF. Mean peak LH and FSH among Norplant implants users who ovulated were three- to four-fold lower than among controls. Although users of Norplant implants with regular cycles frequently have luteal activity, the results of this study suggest that elevation of P during the second half of the cycle does not necessarily indicate ovulation has occurred and may frequently be associated with the presence of luteinized unruptured follicle. When ovulation occurs, there are usually abnormal hormone levels (low LH/FSH peak, low progesterone) which may also contribute to the contraceptive effect of Norplant implants.

Entities:  

Keywords:  Americas; Anovulation; Biology; Caribbean; Contraception; Contraceptive Agents; Contraceptive Agents, Female; Contraceptive Agents, Progestin; Contraceptive Implants; Contraceptive Methods; Developing Countries; Dominican Republic; Endocrine System; Family Planning; Follicle Stimulating Hormone; Genitalia; Genitalia, Female; Gonadotropins; Gonadotropins, Pituitary; Hormones; Latin America; Levonorgestrel; Luteinizing Hormone; North America; Ovarian Effects; Ovary; Ovulation; Physiology; Progestational Hormones; Progesterone; Prospective Studies; Reproduction; Research Methodology; Research Report; Studies; Ultrasonics; Urogenital System

Mesh:

Substances:

Year:  1996        PMID: 8934060     DOI: 10.1016/s0010-7824(96)00179-5

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  3 in total

1.  Levonorgestrel hormone releasing intrauterine system (Mirena) as a contraceptive in egg donors: case report.

Authors:  C Kailasam; V Akande; U D Gordon
Journal:  J Assist Reprod Genet       Date:  2005-03       Impact factor: 3.412

Review 2.  Levonorgestrel subdermal implants. A review of contraceptive efficacy and acceptability.

Authors:  A J Coukell; J A Balfour
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

Review 3.  Drug interactions between hormonal contraceptives and antiretrovirals.

Authors:  Kavita Nanda; Gretchen S Stuart; Jennifer Robinson; Andrew L Gray; Naomi K Tepper; Mary E Gaffield
Journal:  AIDS       Date:  2017-04-24       Impact factor: 4.177

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.